RxDoctor Payments Data

Joseph Obuba

Family · Decatur, GANPI 1043630627

Payments from drug & device makers

$4,730in general payments, 2019–2025

Across 214 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$535
  • Teva Pharmaceuticals USA, Inc.$499
  • Vanda Pharmaceuticals Inc.$282
  • Lundbeck LLC$225
  • plus $692 from 6 others

What the payments were for

  • Food & beverage$4,60897%
  • Education$1223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,730 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$2,283
Medicare patients
16
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$71,920
Invega SustennaPaliperidone Palmitate28$62,102
VraylarCariprazine Hcl21$30,301
TrintellixVortioxetine Hydrobromide13$6,244
Aripiprazole30$1,683
Divalproex Sodium30$799
Lurasidone Hcl25$661
Olanzapine27$589
Quetiapine Fumarate43$436
Haloperidol18$427
Fluoxetine Hcl84$400
Risperidone58$385
Hydroxyzine Pamoate40$367
Venlafaxine Hcl ErVenlafaxine Hcl28$340
Sertraline Hcl45$337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$499$71,92012 claims
Johnson & JohnsonInvega Sustenna$1,041$62,10228 claims
AbbVieVraylar$1,455$30,30121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →